FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEM
Section 16. Form 4 or Form 5	
obligations may continue. See	

MENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

obligations Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Holtzman Steven H						2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]									ck all appli Directo	ationship of Reportin all applicable) Director Officer (give title		g Person(s) to Issuer 10% Owner Other (specify	
	(F N IDEC INC NEY STRE	<u>.</u>	(Middle)					est Tran	saction (N	/lonth/	Day/Year)	X	below) "		below) te Development		` <i>`</i>		
(Street) CAMBR (City)	IDGE M	[A (02142 (Zip)		4. li	Line) X Form filed											oint/Group Filing (Check Applicable ed by One Reporting Person ed by More than One Reporting		
		Tab	le I - No	n-Deriv	/ative	Sec	uriti	ies Ac	quired	, Dis	posed o	of, or B	enefi	cially	Owned	t			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Dat if any (Month/Day/Yo		on Date,	Code (Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			Benefici Owned	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Ownership		
						Code	v	Amount	(A) (D)	Pri	се	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)			
Common	Stock			02/01	/2015				М		5,157	A		\$0	5,	,157 D			
Common	Stock			02/01	/2015				F		2,060	D	\$3	89.16	3,	,097 D			
		T	able II -								osed of converti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Executior if any (Month/Da	n Date,	Code (In:		ion of		6. Date E Expiratio (Month/D	n Date	Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		of es ing /e Secu	1 2	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amo or Num of Shar	ber					
Restricted Stock Unit	\$0 ⁽¹⁾	02/01/2015			M			5,157	(2)	()2/01/2015	Commo	5,1	57	\$0	0		D	

Explanation of Responses:

- 1. There is no conversion or exercise price for this stock unit.
- 2. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

Matthew S. Gilman, Attorneyin-Fact for Steven H. Holtzman

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.